In addition to contributing to tumorigenicity, PHGDH may contribute to innate or acquired resistance to current chemotherapies in cancer (134). In vitro and in vivo, small molecules inhibit the serine synthesis pathway of PHGDH, resulting in a lower proliferation rate of breast cancer cells expressing PHGDH (135, 136). The gene discussed is PHGDH; the disease is breast carcinoma.